ClinicalTrials.gg
CompletedNCT03322514ProApUpdated Nov 20, 2019Results posted

Colonic Propionate, Appetite, and Weight Loss

An interventional study of Inulin-Propionate Esters and Inulin in Healthy Obesity, Metabolically and Appetite Regulation, sponsored by Imperial College London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-20.

Sponsored by Imperial College London · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The current protocol aims to investigate the impact of the propionate ester in conjugation with restricted diet on appetite and weight loss.

Read the detailed description

DIET AND OBESITY:

Obesity has reached epidemic proportions worldwide. In the United Kingdom, 58% of adult women and 65% of adult men are either overweight or obese (Health and Social Care Information Centre 2014), with the expectation that rates will increase (Ng et al. 2014). Obesity, mainly caused by a chronic positive energy balance, is a known risk factor that contributes to the development of type 2 diabetes and cardiovascular diseases, and the subsequent morbidities and mortalities (Kopelman 2007). A positive energy balance is inevitable with the composition of current western diet that contain refined (fibre-depleted) carbohydrates that are consumed quickly, and have minimal effects on long-term satiety (Cleave 1974; Heaton 1973).

NONDIGESTIBLE CARBOHYDRATES:

The quality and quantity of diet has changed dramatically over the last fifty years. Of which, carbohydrates have the most significant changes; from unprocessed fruits and vegetables based carbohydrates to more processed cereal based ones (Cordain et al. 2005). Epidemiological studies have shown that, as a result, ancestral diets had greater amounts of Non-Digestible Carbohydrates (NDC) than modern diets (>100g/day compared to \<15g/day) with the inclusion of more indigestible intact cell wall plant material, such as tubers, grasses and sedges (Eaton 2006). A strong association has been established between increased weight gain with decreased NDC intake (Liu et al. 2003). Furthermore, increasing intake of NDC have shown to induce satiety and improve body composition in animals (So et al. 2007) and humans (Bouché et al. 2002).

LOW CALORIC HIGH NDC DIET IN LOSING WEIGHT Applying energy-restricted diets is one of the first steps to treat obesity. However, weight regain in weight maintenance period could happen due to resting energy expenditure reduction and lean mass loss. The inclusion of specific foods to the nutritional intervention is being investigated in order to produce persistent weight losses (Abete et al. 2008). It was suggested earlier that the addition of high fibre NDC foods to a hypocaloric diet would help reducing the incidence of metabolic syndrome and increasing the dietary compliance (Hermana et al, 2011). The high fibre content in combination with a low glycemic index diet, can both result in higher satiety effects with an increased mitochondrial oxidation, all favour weight loss.

PROPIONATE AND THE FFAR2 RECEPTOR:

Production of short chain fatty acids (SCFA) is the main by-product of NDC colonic fermentation (Pawlak et al. 2004). Of them, colonic propionate was found to play a critical role directly in the colon and systematically after its absorption into the circulation (Wong et al. 2006). Free Fatty Acid Receptor 2 (previously known as orphan G-coupled Protein Receptor 43) has been discovered to has high affinity to propionate (Brown et al. 2003). It is expressed on the distal ileum and colon L-enteroendocrine cells (Karaki et al. 2008), adipocytes and certain monocytes lineage (Hong et al. 2005).

THE ROLE OF PROPIONATE IN GUT HORMONE RELEASE AND APPETITE REGULATION:

The L-enteroendocrine colonic cells are responsible of secreting anorexic gut hormones (PYY and GLP-1) physiologically in response to food. These hormones are capable of inducing satiety through signalling the brain appetite centre (Murphy \& Bloom 2006). Propionate-induced FFAR2 activation have found to cause the release of these hormones in vitro. Moreover, NDC ingestion was found to stimulate the release of these hormones in animals, resulting in decreasing food ingestion (Delzenne et al. 2005). Propionate was shown to replicate the same effects in further studies, suggesting the owning of the beneficial effects of NDC on appetite and gut hormones to propionate production.

SHORT CHAIN FATTY ACID ESTER:

Administering NDCs that promote the production of propionate is an attractive way to increase the level of propionate over an extended period of time. However, due to variability of the gut microbita activity, administering high proportions (≥ 35g/d) of dietary fibres in human diets to increase colonic propionate does not reliably or predictably provide the same SCFA levels in colon or systemically (Cummings 1981). Oral propionate supplementation is another method, but unfortunately its short plasma half-life, poor palatability, and the fact that its main absorption happens in the small intestine limit its use as a food supplement (Frost et al. 2003).

A novel system has been developed by Dr Douglas Morrison, (Scottish Universities Environmental Research Centre (SUERC)). This molecule of inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester) was demonstrated to reliably and reproducibly increase colonic propionate while prevent the side effects of NDC (Chambers et al. 2015). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora, which was estimated to be 180 minutes post-ingestion. (Chambers et al. 2014). Chambers et al. (2015) were able to show that 10g of Inulin-Propionate Esters (IPE) has the ability to deliver 2.4g of propionate to the colon, that is an increment of 2.5-fold of propionate production in the colon, a level that is achieved only with 60g/d via traditional dietary fibre supplementation. The same group has also demonstrated that while the acute administration of this supplement caused increments in Plasma GLP-1 and PYY and reduced food ingestion, the long term (24 weeks) supplementation of propionate ester significantly reduced body weight gain and the development of abdominal adipose tissue (Chambers et al. 2014). Interestingly, none of the long term participants reported any side effects from the intake of propionate esters. Increasing colonic propionate is, therefore, one of the attractive strategies to manage weight and diabetes risk factors.

The current protocol aims to investigate the impact of the propionate ester in conjugation with restricted diet on appetite and weight loss.

02

Conditions studied

  • Healthy Obesity, Metabolically
  • Appetite Regulation

Keywords

  • gut hormones
  • obesity
  • appetite
  • propionate
  • fermentation
03

In context

Obesity, Metabolically Benign

27 studies on the registry are indexed under Obesity, Metabolically Benign; 8 are open to participants now.

This study's enrollment of 12 is below the median of 60 across 17 interventional studies indexed under Obesity, Metabolically Benign.

Browse Obesity, Metabolically Benign studies →

Lead sponsor

Imperial College London is the lead sponsor of 843 studies on the registry; 180 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • overweight or obese (() of 25-35 kg/m2)
  • healthy
  • aged between 18 and 65 years

Exclusion criteria

Exclusion Criteria:

  • Weight change of ≥ 3kg in the preceding 2 months
  • Undergone any weight loss surgery or gastric procedures to promote weight loss
  • Current smokers
  • Substance abuse
  • Excess alcohol intake
  • Pregnancy
  • Diabetes
  • Cardiovascular disease
  • Cancer
  • Gastrointestinal disease e.g. inflammatory bowel disease or irritable bowel syndrome
  • Kidney disease
  • Liver disease
  • Pancreatitis
  • Use of medications likely to interfere with energy metabolism, appetite regulation and hormonal balance, including: anti-inflammatory drugs or , antibiotics, androgens, phenytoin, erythromycin or thyroid hormones.

Any participants with the above conditions would already have an altered pattern of hormones and inflammatory molecules because of their disease process and would therefore give us confounding or misleading results.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    experimental group

    10 g of Inulin-Propionate Esters will be administered per day

    Dietary Supplement: Inulin-Propionate Esters

  • Active comparator
    Inulin

    10 g of Inulin will be administered per day

    Dietary Supplement: Inulin

Interventions

  • Dietary supplementInulin-Propionate Esters

    Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.

  • Dietary supplementInulin

    Inulin

06

What researchers measure

Primary outcomes

  1. Change in Weight Loss Compared to Baseline

    The weight assessed by a body scale

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Glucose Blood Level Baseline to 12 Weeks

    Time frame: Baseline, 12 weeks

  2. Insulin Level in Serum

    Time frame: Baseline, 12 weeks

07

Results

Posted Nov 7, 2019

Participant flow

Participant flow — Overall Study
MilestoneExperimental GroupInulin
Started66
Completed55
Not completed11
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryChange in Weight Loss Compared to Baseline

The weight assessed by a body scale

Time frame:
Baseline and 12 weeks
Reported as:
Mean · kg
Change in Weight Loss Compared to Baseline
kgExperimental GroupInulin
Change in Weight Loss Compared to Baseline-2.6 ± 0.9-3 ± 1.04
Statistical analysis
  • Experimental Group vs Inulin · t-test, 2 sided · p = 0.8
  • Experimental Group · t-test, 2 sided · p = 0.04
  • Inulin · t-test, 2 sided · p = 0.1
SecondaryGlucose Blood Level Baseline to 12 Weeks
Time frame:
Baseline, 12 weeks
Reported as:
Mean · mmol/L
Glucose Blood Level Baseline to 12 Weeks
mmol/LExperimental GroupInulin
Baseline4.9 ± 0.14.4 ± 0.1
12 weeks5.1 ± 0.14.8 ± 0.1
Statistical analysis
  • Experimental Group vs Inulin · ANOVA · p = 0.8
  • Experimental Group · t-test, 2 sided · p = 0.3
  • Inulin · t-test, 2 sided · p = 0.3
SecondaryInsulin Level in Serum
Time frame:
Baseline, 12 weeks
Reported as:
Mean · mU/mL
Insulin Level in Serum
mU/mLExperimental GroupInulin
Baseline50.4 ± 10.848.9 ± 18.3
12 weeks41.0 ± 6.746.0 ± 21.1
Statistical analysis
  • Experimental Group vs Inulin · ANOVA · p = 0.9
  • Experimental Group · t-test, 2 sided · p = 0.4
  • Inulin · t-test, 2 sided · p = 0.7

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Group0/6 (0%)0/6 (0%)0/6 (0%)
Inulin0/6 (0%)0/6 (0%)0/6 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Experimental GroupInulinTotal
<=18 years000
Between 18 and 65 years6612
>=65 years000
Age, Continuous
Age, Continuous(years)Experimental GroupInulinTotal
Mean30.6 ± 5.935.2 ± 12.133.4 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Experimental GroupInulinTotal
Female459
Male213
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Experimental GroupInulinTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Experimental GroupInulinTotal
United Kingdom6612
08

Study locations

1 site
  • NIHR/Wellcome Trust Imperial Clinicial Research Facility
    London, W12 0NN, United Kingdom
09

References and documents

Publications

  • M. Khatib, E. Chambers, D. Morrison and G. Frost. A pilot study to evaluate the effect of increased colonic propionate on appetite during a hypocaloric diet. Proceedings of the Nutrition Society (2018), 77 (OCE4), E119.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Nov 2017, 7 months.

Results were first posted in Nov 2019, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2017
First posted
Oct 26, 2017
StartActual
Mar 29, 2017
Primary completionActual
Nov 11, 2017
CompletionActual
Nov 11, 2017
Results first posted
Nov 7, 2019
Last update
Nov 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03322514
Responsible party
Sponsor
First posted
Oct 26, 2017
Start date
Mar 29, 2017
Primary completion
Nov 11, 2017
Completion
Nov 11, 2017
Results posted
Nov 7, 2019
Last update
Nov 20, 2019

Study contacts

Gary Frost
principal investigator · Dietitian; PhD in Nutrition; Professor of nutrition and dietetics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion